On June 30, 2026 Ratio Therapeutics Inc. (Ratio), a clinical-stage pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment, reported that it has entered into a strategic supply agreement with PanTera, an innovative producer scaling the supply of vital medical radionuclides, supporting Ratio’s ongoing efforts to build a robust and scalable supply infrastructure for its radiopharmaceutical development programs.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The agreement provides Ratio with access to dedicated Ac-225 supply and establishes a framework for future expansion as the company’s development needs evolve. The agreement will support Ratio’s clinical-stage radiotherapeutic programs while further strengthening Ratio’s manufacturing and supply chain foundation required to advance targeted alpha therapies.
"Building a resilient and diversified supply network is an important component of our long-term strategy as we advance our radiopharmaceutical pipeline," said Matthias Friebe, Chief Development Officerof Ratio Therapeutics. "PanTera has emerged as an important contributor to the global Actinium-225 ecosystem, and this agreement reflects our commitment to establishing the infrastructure needed to support ongoing clinical development of our radiotherapies."
"We are honored to partner with Ratio Therapeutics to support the advancement of their innovative radiopharmaceutical pipeline," said Christophe Malice, CBO of PanTera. "Ratio’s targeted approach to treating cancer exemplifies the kind of clinical progress enabled by reliable Ac-225 supply. By providing dependable Ac-225, produced in compliance with cGMP, we are proud to help ensure that programs such as Ratio’s can advance without the supply constraints that have long challenged the field. This collaboration reflects PanTera’s commitment to supporting the pharmaceutical industry as it works to bring next-generation targeted therapeutics to patients in need."
As demand for targeted alpha therapies continues to increase across the industry, reliable access to critical radioisotopes such as Ac-225 has become increasingly important. Through strategic collaborations with leading suppliers and manufacturing partners, Ratio continues to strengthen the supply chain necessary to support the development of its therapeutic candidates.
(Press release, Ratio Therapeutics, JUN 30, 2026, View Source [SID1234669013])